Prism Research   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: King of Prussia PA United States (2004)
Status: Acquired by Baxalta (2011) → now Takeda (2018)

Organization Overview

First Clinical Trial
2006
NCT00420953
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prism Clinical Research | Prism Pharmaceuticals | Prism Pharma Co., Ltd. | Prism Research Clinic | Prism Research Inc. | Prism Research, Inc | Prism Research, Inc. | Prism Research, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Essential Hypertension (Phase 1)

Fatty Liver (Phase 1)

Fibrosis (Phase 2)

Heart Failure (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis C (Phase 2)

Hyperglycemia (Phase 1)

Hypertension (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Cirrhosis (Phase 2)

Migraine Disorders (Phase 1)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Pancreatic Neoplasms (Phase 1)

Pneumonia (Phase 1)

Psoriasis (Phase 2)

Rabies (Phase 3)

Renal Insufficiency (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial APIs: 25